Résumé
Les antagonistes muscariniques, comme l’oxybutynine, sont le principal traitement pharmacologique actuel pour l’incontinence urinaire par urgenturie. L’objectif de cette étude a été d’évaluer l’activité pharmacologique de l’oxybutynine sur la fonction vésicale chez la souris. Pour cela, nous avons développé des nouveaux modèles expérimentaux nous permettant d’étudier, in vitro, sa puissance antagoniste sur la vessie isolée et in vivo, son urosélectivité au regard des effets sur les glandes salivaires ainsi que ses effets sur le cycle mictionnel en utilisant la technique de cystomanométrie. L’ensemble des résultats présenté est en accord avec ceux publiés chez l’homme. Cette espèce apparaît être un modèle pertinent pour étudier la fonction vésicale.
Abstract
Muscarinic antagonists, such as oxybutynin, provide the most common pharmacological treatments for urge urinary incontinence. The aim of the present study is to evaluate the pharmacological effects of oxybutynin on bladder function in mice. We constructed new experimental models allowing us to study the in vitro antagonistic effects on strips of bladder detrusor smooth muscle, in vivo uroselectivity (effects on vesical pressure and salivary glands), and the effect on micturition cycles using cystometry. Overall, our results agree with previous results reported in studies of humans. Therefore, mice offer an appropriate model to study bladder function.
Références
Andersson KE, Arner A (2004) Urinary bladder contraction and relaxation: physiology and pathophysiology. Physiol Rev 84: 935–986
Yoshida M, Homma Y, Inadome A, et al. (2001) Agerelated changes in cholinergic and purinergic neurotrans-mission in human isolated bladder smooth muscles. Exp Gerontol 36: 99–109
Palea S, Artibani W, Ostardo E, et al. (1993) Evidence for purinergic neurotransmission in human urinary bladder affected by interstitial cystitis. J Urol 150: 2007–2012
O’Reilly BA, Kosaka AH, Knight GF, et al. (2002) P2X receptors and their role in female idiopathic detrusor instability. J Urol 167: 157–164
Haab F, Amarenco G, Coloby P, et al. (2004) Terminologie des troubles fonctionnels du bas appareil urinaire: adaptation française de la terminologie de l’International Continence Society. Progrés en urologie 14: 1103–1111
de Groat WC (1997) A neurologic basis for the overactive bladder. Urology 50: 36–52 (discussion, pp 53–6)
Brading AF (1997) A myogenic basis for the overactive bladder. Urology 50: 57–67
Herbison P, Hay-Smith J, Ellis G, et al. (2003) Effectiveness of anticholinergic drugs compared with placebo in the treatment of overactive bladder: systematic review. BMJ 326: 841–844
Yarker YE, Goa KL, Fitton A (1995) Oxybutynin. A review of its pharmacodynamic and pharmacokinetic properties, and its therapeutic use in detrusor instability. Drugs Aging 6: 243–262
Andersson KE, Yoshida M (2003) Antimuscarinics and the overactive detrusor-which is the main mechanism of action? Eur Urol 43: 1–5
Modiri AR, Alberts P, Gillberg PG (2002) Effect of muscarinic antagonists on micturition pressure measured by cystometry in normal, conscious rats. Urology 59: 963–968
Peterson JS, Hanson RC, Noronha-Blob L (1989) In vivo cystometrogram studies in urethane-anesthetized and conscious guinea pigs. J Pharmacol Methods 21: 231–241
Finney SM, Andersson KE, Gillespie JI, et al. (2006) Antimuscarinic drugs in detrusor overactive bladder syndrome: motor or sensory actions? BJU Int 98: 503–507
Mukerji G, Yiangou Y, Grogono J, et al. (2006) Localization of M2 and M3 muscarinic receptors in human bladder disorders and their clinical correlations. J Urol 176: 367–373
Angelico P, Velasco C, Guarneri L, et al. (2005) Urodynamic effects of oxybutynin and tolterodine in conscious and anesthetized rats under different cystometrographic conditions. BMC Pharmacol 5: 14
Abrams P, Andersson KE, Buccafusco JJ, et al. (2006) Muscarinic receptors: their distribution and function in body systems and the implications for treating overactive bladder. Br J Pharmacol 148: 565–578
Nakamura T, Matsui M, Uchida K, et al. (2004) M3 muscarinic acetylcholine receptor plays a critical role in parasympathetic control of salivation in mice. J Physiol 558: 561–575
Hegde SS (2006) Muscarinic receptors in the bladder: from basic research to therapeutics. Br J Pharmacol 147: S80–S87
Ohtake A, Ukai M, Hatanaka T, et al. (2004) In vitro and in vivo tissue selectivity profile of solifenacin succinate (YM905) for urinary bladder over salivary gland in rats. Eur J Pharmacol 492: 243–250
Palea S, Lluel P, Barras M, et al. (2004) Involvement of 5-hydroxytryptamine (HT)7 receptors in the 5-HT excitatory effects on the rat urinary bladder. BJU Int 94: 1125–1131
Lluel P, Barras M, Palea S (2002) Cholinergic and purinergic contribution to the micturition reflex in conscious rats with long-term bladder outlet obstruction. Neurourol Urodyn 21: 142–153
Pandita RK, Fujiwara M, Alm P, et al. (2000) Cystometric evaluation of bladder function in non-anesthetized mice with and without bladder outlet obstruction. J Urol 164: 1385–1389
Oki T, Sato S, Miyata K, et al. (2005) Muscarinic receptor binding, plasma concentration and inhibition of salivation after oral administration of a novel antimuscarinic agent, solifenacin succinate in mice. Br J Pharmacol 145: 219–227
Kobayashi S, Ikeda K, Miyata K (2004) Comparison of in vitro selectivity profiles of solifenacin succinate (YM905) and current antimuscarinic drugs in bladder and salivary glands: a Ca2+ mobilization study in monkey cells. Life Sci 74: 843–853
Nelson CP, Gupta P, Napier CM, et al. (2004) Functional selectivity of muscarinic receptor antagonists for inhibition of M3-mediated phosphoinositide responses in guinea pig urinary bladder and submandibular salivary gland. J Pharmacol Exp Ther 310: 1255–1265
Igawa Y, Zhang X, Nishizawa O, et al. (2004) Cystometric findings in mice lacking muscarinic M2 or M3 receptors. J Urol 172: 2460–2464
Deba A, Lluel P, Palea S (2006) Mesure simultanée de la salivation et de la pression intravésicale chez la souris anesthésiée: effets de l’oxybutynine. Pelv Perineol 1: 93–94
Matsuura S, Downie JW (2000) Effect of anesthetics on reflex micturition in the chronic cannula-implanted rat. Neurourol Urodyn 19: 87–99
Chess-Williams R, Chapple CR, Yamanishi T, et al. (2001) The minor population of M3-receptors mediate contraction of human detrusor muscle in vitro. J Auton Pharmacol 21: 243–248
De Laet K, De Wachter S, Wyndaele JJ (2006) Systemic oxybutynin decreases afferent activity of the pelvic nerve of the rat: new insights into the working mechanism of antimuscarinics. Neurourol Urodyn 25: 156–161
Kim Y, Yoshimura N, Masuda H, et al. (2005) Antimuscarinic agents exhibit local inhibitory effects on muscarinic receptors in bladder-afferent pathways. Urology 65: 238–242
de Groat WC (2004) The urothelium in overactive bladder: passive bystander or active participant? Urology 64: 7–11
Bassuk JA, Grady R, Mitchell M (2000) Review article: the molecular era of bladder research. Transgenic mice as experimental tools in the study of outlet obstruction. J Urol 164: 170–179
Author information
Authors and Affiliations
Corresponding author
Rights and permissions
About this article
Cite this article
Deba, A., Lluel, P. & Polea, S. Propriétés pharmacologiques de l’oxybutynine sur la fonction vésicale chez la souris. Pelv Perineol 2, 12–19 (2007). https://doi.org/10.1007/s11608-007-0108-2
Published:
Issue Date:
DOI: https://doi.org/10.1007/s11608-007-0108-2